Tempus AI’s stock surged over 11% after its third-quarter report showed revenue of $411.54 million, beating expectations and marking its sixth consecutive quarter of positive adjusted EPS. The company raised its full-year revenue forecast to $1.60-$1.605 billion and expects adjusted EBITDA around $65 million. Major ETFs such as ARK Innovation and ARK Genomic Revolution hold significant positions in Tempus, giving investors in these funds indirect exposure. Upcoming events including the Personalis shareholder vote and new test pricing in 2027 could further impact the stock. Tempus AI’s stock price jumped 11.80% to USD 80.75 on Pluang as of Nov 03, 2026 03:01 WIB, nearing its 52-week high of USD 89.85. In contrast, the ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG), which hold significant Tempus positions, fell 1.36% and 4.82% respectively, with ARKK at USD 79.75 and ARKG at USD 48.94.